Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

42 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-10-31

Study Completion Date

2015-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to test a new approach to the use of standard drugs before surgery in patients with lung cancer. This study will find out what effects, good and/or bad, that this approach has on the cancer.

It is routine to give chemotherapy prior to surgery in patients with this type of lung cancer, to help keep it from coming back. It is also routine to perform a special type of scan called a PET scan. This PET scan measures how active a cancer is by use of a special tracer made out of sugar. In this study, all patients will have a PET scan and then be treated with standard chemotherapy drugs, either pemetrexed and cisplatin if the cancer is a "non-squamous" cancer or gemcitabine and cisplatin if the cancer is a squamous cancer. In rare cases, the doctor will decide to give carboplatin instead of cisplatin. In most patients, a repeat PET scan will show that the tumor is decreasing and they will complete standard chemotherapy then go on to have surgery.

In some patients, a repeat PET scan will show that the tumor has not decreased enough. For these patients, the routine practice is to proceed with surgery. This research study will test whether switching from the standard treatment of pemetrexed and cisplatin or gemcitabine and cisplatin to a different treatment called vinorelbine and docetaxel is safe and effective. Vinorelbine and docetaxel are also standard chemotherapy drugs which work in a different way than pemetrexed or gemcitabine and cisplatin.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Preoperative Therapy in Patients With Stages IB, II, IIIA, and Selected IIIB Patients With Non-Small Cell Lung Cancer

NCT00193427

Lung Cancer

COMPLETED PHASE2

A Phase II Clinical Trial of Docetaxel, Oxaliplatin Combination Chemotherapy in Patients With Stage IIIB/IV Non-adenocarcinoma, Non-small Cell Lung Cancer (NSCLC) as Second-line Treatment

NCT01497041

Carcinoma, Non-Small-Cell Lung Carcinoma, Squamous Carcinoma, Large Cell

UNKNOWN PHASE2

A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy

NCT04151563

Carcinoma, Non-small Cell Lung Cancer

WITHDRAWN PHASE1/PHASE2

FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer

NCT00020202

Extensive Stage Small Cell Lung Cancer Stage IIIA Non-small Cell Lung Cancer Stage IV Non-small Cell Lung Cancer +3 more

COMPLETED PHASE2

Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

NCT05800587

Lung Cancer Small-cell Lung Cancer Non Small Cell Lung Cancer

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

pemetrexed plus cisplatin, vinorelbine and docetaxel

This is a phase 2 clinical trial for patients with clinical Stage IB-III resectable and operable non-small cell lung cancer, evaluating whether the switch to an alternative, non-platinum neoadjuvant chemotherapy is safe and effective in patients who do not respond to neoadjuvant platinum-based chemotherapy. Those who fail to respond to platinum-based chemotherapy will be switched to the alternative neoadjuvant chemotherapy vinorelbine 45 mg/m2 and docetaxel 45 mg/m2 on day 1 followed by pegylated filgrastim on day 2, repeated every 2 weeks for 4 doses, followed by repeat FDG PET and CT scan.

Group Type EXPERIMENTAL

pemetrexed

Intervention Type DRUG

cisplatin

Intervention Type DRUG

Carboplatin

Intervention Type DRUG

Gemcitabine Hydrochloride

Intervention Type DRUG

Vinorelbine Tartrate

Intervention Type DRUG

Docetaxel

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

pemetrexed

Intervention Type DRUG

cisplatin

Intervention Type DRUG

Carboplatin

Intervention Type DRUG

Gemcitabine Hydrochloride

Intervention Type DRUG

Vinorelbine Tartrate

Intervention Type DRUG

Docetaxel

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Pathologic confirmation of NSCLC at MSKCC
* Stages IB, IIA, IIB, IIIA or IIIB NSCLC
* Primary tumor must measure ≥ 2 cm on CT imaging (per PERCIST guidelines)
* Primary tumor must be FDG-avid with an SUVmax \>4.5 (to be consistent with PERCIST guidelines)
* Patients must be candidates for resection with curative intent
* Age ≥ 18 years
* Karnofsky performance status ≥ 70%
* Normal bone marrow function
* leukocytes ≥ 3,000/μl
* absolute neutrophil count ≥ 1,500/μl
* platelets ≥100,000/μl
* hemoglobin ≥9gm/dl.
* Adequate hepatic function
* Total bilirubin ≤1.5 x ULN
* AST ≤ 1.5 x UNL, ALT ≤ 1.5 x ULN
* Alkaline phosphatase ≤ 1.5x ULN
* Women of childbearing age must have a negative pregnancy test
* Men and women of childbearing potential must be willing to use effective contraception while on treatment and for at least 3 months thereafter
* Patients must have the ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria

* Patients must not be receiving any other investigational agents
* History of myocardial infarction or unstable angina within the past 12 months Patients with peripheral neuropathy \> grade 1
* Other serious illness or medical condition including unstable cardiac disease requiring treatment, history of significant neurologic or psychiatric disorders (including psychotic disorders, dementia, or seizures), or active uncontrolled infection.
* Patients with diabetes mellitus requiring insulin therapy (per PERCIST guidelines)
* Patients with third space fluid which cannot be adequately controlled with drainage
* Women who are pregnant or breast-feeding
* Psychiatric illness or social situation that would limit compliance with study requirements
* Patients with known HIV infection requiring antiretroviral medications and those with AIDS
* Baseline subjective hearing deficit, even if it does not require a hearing aid or intervention, or interfere with activities of daily living (CTCAE grade 2 or higher)
* Baseline renal function \<60 ml/min as calculated by the equation of Cockcroft and Gault using the patient's age, weight (kg), and serum creatinine (mg/dl).
* Congestive heart failure with New York Heart Association functional classification \> II, characterized by fatigue, dyspnea or other symptoms which limit activities of daily life.

Selection of Pemetrexed versus Gemcitabine: Patients treated with pemetrexed must meet all of the following criteria:

* Non-squamous histology
* Patients must have the ability to interrupt non-steroidal anti-inflammatory drugs (NSAIDs) 2 days before (5 days for long-acting NSAIDs), the day of, and 2 days following administration of pemetrexed
* Patients must have the ability to take folic acid, Vitamin B12, and dexamethasone according to protocol
* Patient refuses to take cisplatin

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No